Stories

Molecular glues are a new type of medicine inspired by nature’s matchmakers.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

The recently appointed leader of the Novartis’ digital research and development platform data42 is a strong believer that data and digital technologies will change the path of medical science.

Researchers race to put hydroxychloroquine to the test in a large study.

Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.

Phil Gotwals talks about his vision for the future of business development for research.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

For all too many people living with heart failure, hospitalizations are a recurring part of life, affecting the lives of both patients and their caregivers.

Novartis researchers are learning how a novel approach to immunotherapy could help treat cancer.

Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.

We leave the lab to find out what people know about cell and gene therapy.

Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.